<p>This study is from a phase I clinical trial of neoantigen DNA vaccines in triple negative breast cancer patients with persistent disease following neoadjuvant chemotherapy. The exome and RNA sequences used to identify somatic mutations, predict neoantigens, and design vaccines is within.<br></p>

Personalized Breast Cancer Vaccines Based on Genome Sequencing

Triple Negative Breast Neoplasms study with AMPLICON, RNA-Seq + 1 more data on dbGaP (18 participants)